Hosted on MSN5h
Canaccord Genuity Upgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...
SpotDraft taps AI to help streamline contract management
SpotDraft, a contract lifecycle management platform with AI-powered features, has raised $54 million in a new funding round.
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...
Mother Jones11h
Project 2025 Is Gutting Medical Funding That Helped Russell Vought’s Own Kid
Its architect's daughter has cystic fibrosis—and benefits from a "miracle drug" backed by an agency he's attacking.
Vertex Pharmaceuticals EVP Ourania Tatsis sells $142,547 in stock
BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...
Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...
Vertex Pharmaceuticals price target raised to $520 from $460 at Truist
Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares ...